KDM1A Inhibitors for Disease Treatment Patent Application

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a new patent application (US20260085082A1) from Imago Biosciences, Inc. The application discloses new compounds and compositions for pharmaceutical use, specifically for inhibiting KDM1A and increasing gamma globin gene expression to treat diseases like acute myelogenous leukemia.

View original document View source feed page

What changed

This document is a published patent application from the USPTO, detailing new compounds and compositions developed by Imago Biosciences, Inc. The application, identified as US20260085082A1, focuses on KDM1A inhibitors for pharmaceutical applications, including methods for treating diseases such as acute myelogenous leukemia by increasing gamma globin gene expression and inducing cancer cell differentiation.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future developments in drug discovery and treatment for certain cancers. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in oncology or hematology research, should be aware of this filing as it may impact their intellectual property landscape and competitive strategies.

Source document (simplified)

← USPTO Patent Applications

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Application US20260085082A1 Kind: A1 Mar 26, 2026

Assignee

Imago Biosciences, Inc.

Inventors

Hugh Y. Rienhoff, Jr., Cassandra Celatka, Amy E. Tapper, Nivedita Namdev, Michael Clare

Abstract

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

CPC Classifications

C07F 9/65583 A61K 31/4155 A61K 31/454 A61K 31/4545 A61K 31/496 A61K 31/541 A61K 31/675 A61K 31/706 A61P 35/02 C07D 231/40 C07D 401/06 C07D 401/12 C07D 401/14 C07D 403/06 C07D 403/10 C07D 403/12 C07D 405/14 C07D 413/14 C07D 417/14 C07D 491/056